Emerging antimicrobial therapies for Gram-negative infections in human clinical use

Abstract The growing problem of multi-drug resistance (MDR) is prevalent in Gram-negative infections, and the significant decline in antibiotic development poses a critical threat to global public health. Many emerging non-antibiotic therapies have been proposed, including phage therapy, anti-virule...

Full description

Saved in:
Bibliographic Details
Main Authors: Sarah M. Hickson, Emma L. Ledger, Timothy J. Wells
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:npj Antimicrobials and Resistance
Online Access:https://doi.org/10.1038/s44259-025-00087-2
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The growing problem of multi-drug resistance (MDR) is prevalent in Gram-negative infections, and the significant decline in antibiotic development poses a critical threat to global public health. Many emerging non-antibiotic therapies have been proposed, including phage therapy, anti-virulence agents, antimicrobial peptides, plasmapheresis, and immunotherapy options. To identify the therapies most likely to be the next immediate step in treatment for MDR Gram-negative infections, this review highlights emerging therapeutics that have either been successfully used for compassionate care or are currently undergoing clinical trials.
ISSN:2731-8745